Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390824 | 1.00 | ATM (0.46) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL1628776 | 0.84 | MMP2 (0.53) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL1629694 | 0.83 | CYP3A4 (0.47) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL3323188 | 0.83 | MMP2 (0.54) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL3323186 | 0.83 | MMP2 (0.54) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL19192088 | 0.82 | ATM (0.46) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL27858541 | 0.82 | CYP3A4 (0.46) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL24535009 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CTSBMEN1KMT2ACYP2C9 | |
| SCHEMBL392112 | 0.80 | ATM (0.46) | ATMALDH1A1CTSLCTSBCTSS | |
| SCHEMBL392111 | 0.80 | ATM (0.46) | ATMALDH1A1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376427-B1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-02 | — | — | EP | claimed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | claimed |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-06-10 | — | — | US | claimed |
| EP-2376427-B1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8486958-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130065916-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8324236-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101794-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ATM 4860/4885ALDH1A1 1569/4885CTSL 1456/4885 |
| US-20130065916-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ATM 4860/4885ALDH1A1 1569/4885CTSL 1456/4885 |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ATM 4860/4885ALDH1A1 1569/4885CTSL 1456/4885 |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ATM 4860/4885ALDH1A1 1569/4885CTSL 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.